ADUS

NEUTRALEarnings

Addus HomeCare Corporation

2026-10-29

Price

$124.34

+1.77%

This is the 2026-10-29 snapshot — the signals and analysis for ADUS as of this single trading day.

View full ADUS research hub →

Score10.5Priority

Signals4/8 DNA2/13 Act · 2/4 Risk

SentimentNEUTRALScore: 8

Volume1.8xvs 20d avg

Analysis

Addus HomeCare (ADUS) is demonstrating High-Conviction Price Discovery, breaking out to a new 52-week high despite a recent BofA downgrade and the delayed closing of its $275M AccentCare acquisition. This price action confirms Institutional Absorption, as buyers aggressively accumulate the stock on 1.7x average volume ahead of its upcoming Q3 earnings. Supported by a RISK_ON macro regime with tight credit spreads and stable volatility, capital is confidently rotating into quality healthcare names with resilient, M&A-driven growth profiles.

Fired Signals

ALPHA MALESTEADY CLIMBGOLDEN CROSSPERFECT STACKQUIET ACCUMULATIONBREAKOUTWEAK FINISHDISTRIBUTION

Key Takeaways

Actionable Thesis: ADUS is exhibiting a high-conviction breakout with a PERFECT_STACK signal, suggesting institutional accumulation ahead of Q3 earnings.
Key Risk: A structural delay or collapse in the pending $275M AccentCare acquisition could trigger a multiple contraction, especially following recent analyst downgrades.
What to Watch: Monitor the upcoming Q3 earnings call for updates on organic growth and the AccentCare deal timeline, holding $111.27 as the structural risk level.

← Back to 2026-10-29 View Full ADUS History →Yahoo Finance &nearr;